Clusterin has been indicated as a potential plasma or cerebrospinal fluid (CSF) biomarker of both PD and Alzheimer’s disease (AD), however, with controversial and non-reproducible results [36–42]. The gene discussed is CLU; the disease is early-onset autosomal dominant Alzheimer disease.